Document text
Principal Investigator: Matthew Memoli
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2024
Award: $123,282
Funding agency: National Institute of Allergy and Infectious Diseases
The SARS-COV-2 virus has had a major impact on morbidity and mortality worldwide, as well as having devastating global economic and societal impact. The overall impact cannot be quantified, some of which is due to the worldwide public health response and not the virus itself. Knowledge of the antibody levels present in a population could offer great insights into current and future response efforts. We need far more information to fully understand what impact immunity will have on the spread and severity of this and future pandemic viruses. This knowledge could change how we handle the next stages of this pandemic, the post pandemic period, and prepare for future pandemics. Therefore, we completed a nationwide serosurvey to enroll a 10,000 person representative sample of the US population to determine how many individuals have been exposed/infected with SARS-CoV-2 during the initial stages of the pandemic. The first portion of this study was published offering insight into the early portion of the pandemic and the epidemiology and immune response early on. We have now published the second portion of this study with a full one year follow up looking at antibody levels over time as well as the influence of vaccines on those antibody levels. This allows us to assess correlates of protection and the trajectory of antibody titers over time. The data yielded from this study, in conjunction with other similar studies can better guide the decisions that are made as this pandemic continues.
We also have an ongoing collaboration with a psychology group at Deakin University who performed a survey study on our serosurvey patients to evaluate personality traits and how that relates to immunity. This study is under review at this time.
In addition to our nationwide serosurvey we initiated a project to study individuals with rare diseases. This study in collaboration with the NCATS RDCRN evaluated how the COVID19 pandemic has affected individuals living with over 500 different rare diseases. The RDCRN has initiated an online survey and we initiated biological sampling to allow us to better identify the level of exposure and immunity in this niche community. The manuscript describing the results of this study are currently under review and the data from this study will allow us to better understand how we can better address the pandemic needs of this community that is often overlooked.
We continue to work in collaboration with Jeff Taubenberger's VPES to develop a broadly protective, universal beta-coronavirus vaccine. We are playing a lead role in the design and manufacture of these vaccines. The work on these vaccines continues.
We also have collaborated with the VPES to investigate various aspects of SARS-COV2 pathogenesis.
We are using data from the N3C program, a national database of COVID cases to investigate differences in infections between male and female patients. This large scale data analysis is near completion and will be published in the coming year.
Lastly, we are working on developing challenge models for beta-coronaviruses that may be used to study pathogenesis as well as testing vaccines. We have successfully GMP manufactured an ODC43 virus and are in discussions with collaborators to initiate a challenge study. We have also begun production of a 229e coronavirus and hope to complete that production this year.
Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><Active Follow-up><Address><Affect><Antibodies><Antibody titer measurement><BetaCoV vaccine><Biological><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 public health crisis><COVID-19 virus><COVID-19 virus infection><COVID-19 years><COVID19 infection><COVID19 virus><CV-19><Clinical><Clinical Trials><CoV-2><CoV2><Collaborations><Communities><Coronaviridae><Coronavirus><Coronavirus Infectious Disease 2019><Data><Data Analyses><Data Analysis><Data Bases><Databases><Decision Making><Differences between sexes><Differs between sexes><Economics><Enrollment><Epidemiology><Future><General Population><General Public><Immune response><Immunity><Immunological response><Individual><Infection><Knowledge><Lead><Manuscripts><Modeling><Morbidity><Morbidity - disease rate><NCATS><National Center for Advancing Translational Sciences><Orphan Disease><Participant><Pathogenesis><Patients><Pb element><Personality><Personality Traits><Persons><Play><Population><Prevalence><Production><Psychology><Public Health><Publishing><Rare Diseases><Rare Disorder><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 pathogenesis><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Sampling><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome related corona virus 2><Severities><Sex Differences><Sexual differences><Survey Instrument><Surveys><Time><Universities><Vaccines><Virus><Work><Wuhan coronavirus><active followup><antibody titering><beta CoV><beta coronavirus><beta coronavirus vaccine><betaCoV><betacoronavirus><betacoronavirus vaccine><biologic><corona virus><coronavirus disease 2019><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 virus><coronavirus infectious disease-19><coronavirus vaccine><data base><data interpretation><design><designing><develop a vaccine><develop vaccines><development of a vaccine><economic><enroll><epidemiologic><epidemiological><evaluate vaccines><female patients><follow up><follow-up><followed up><followup><future pandemic><hCoV19><healthy volunteer><heavy metal Pb><heavy metal lead><host response><immune system response><immunoresponse><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><insight><large scale data><large scale data sets><large scale datasets><male><manufacture><mortality><nCoV2><next pandemic><orphan disorder><panbetaCoV vaccine><pandemic><pandemic disease><pandemic virus><patients being female><patients being women><patients who are female><post-pandemic><programs><response><serology survey><serosurvey><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 pathogenesis><sex based differences><sex-dependent differences><sex-related differences><sex-specific differences><social role><vaccine against coronavirus><vaccine candidate against coronavirus><vaccine development><vaccine evaluation><vaccine screening><vaccine testing><vaccines against betacoronaviruses><vaccines targeting the betacoronavirus><women patients><β CoV><β coronavirus><β coronavirus vaccine><βCoV>